ADMA director granted RSUs and stock options
ADMA Biologics director Jerrold B. Grossman received new equity awards.
Rhea-AI Filing Summary
ADMA Biologics director Jerrold B. Grossman received new equity awards. On February 9, 2026, he was granted 10,690 restricted stock units of common stock at $0, which vest in two equal installments over one year, subject to continued service.
He was also granted stock options for 17,730 shares of common stock at a $16.37 exercise price, with these options vesting in twelve equal monthly installments over one year. Following the grant, he directly beneficially owned 488,884 shares of common stock, including previously granted RSUs, and held additional indirect interests through an LLC, a trust, a foundation, and his spouse.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 28,420 shares
Grant/Award
6 txns
Insider
Grossman Jerrold B
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 17,730 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 10,690 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 17,730 contracts (Direct);
Common Stock — 488,884 shares (Direct);
Common Stock — 92,707 shares (Indirect, See footnote)
Footnotes (7)
- F1. These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.
- F2. Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 472,749 shares of common stock owned by the reporting person.
- F3. These shares are owned by Brookwood LLC ("Brookwood"). The Reporting Person is the managing member of Brookwood.
- F4. These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee.
- F5. These shares are owned by Genesis Foundation Inc. ("Genesis"). The Reporting Person is the President of Genesis.
- F6. These shares are owned by the Reporting Person's wife.
- F7. These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did ADMA director Jerrold Grossman report on February 9, 2026?
Jerrold Grossman reported receiving equity awards from ADMA Biologics, not open‑market trades. He was granted 10,690 restricted stock units and stock options for 17,730 shares, both tied to continued service and time‑based vesting schedules rather than immediate cash purchases or sales.
How many restricted stock units did ADMA’s Jerrold Grossman receive and how do they vest?
He received 10,690 restricted stock units of ADMA common stock at $0. These RSUs vest in two equal installments on the six‑ and twelve‑month anniversaries of the February 9, 2026 grant date, becoming fully vested after one year if he continues in service.
What stock options were granted to ADMA director Jerrold Grossman in this Form 4?
He was granted stock options covering 17,730 ADMA common shares with a $16.37 exercise price. The options vest in twelve equal monthly installments starting from the February 9, 2026 grant date, becoming fully vested after one year, subject to his continued service.
What is Jerrold Grossman’s direct ownership in ADMA common stock after the reported grants?
After the reported transaction, he directly beneficially owned 488,884 ADMA common shares, including RSUs described in the filing. This figure reflects both newly granted and previously outstanding equity awards credited to him as of the transaction date.
Do the new ADMA equity awards to Jerrold Grossman involve any cash purchase or sale?
No cash purchase or sale is reported for these awards. The RSUs are granted at $0, and the stock options are granted at $0 with a $16.37 exercise price, reflecting compensatory grants rather than market transactions involving immediate cash consideration.
AI-generated analysis. How Rhea-AI works. Not financial advice.
